Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia

NCT01518556 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Idarubicin

Sponsor

Konkuk University Medical Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]